On October 13, 2026, San Francisco-based Collective X Health (CX) came out of stealth with an oversubscribed $3.2 million pre-seed round. Council Capital and the Anthemis Female Innovators Lab Fund co-led the round, with participation from SoGal Ventures, Emerson Collective, Muse Capital and Segal Ventures. CX is a B2B "women's health and performance intelligence" platform. It converts peer-reviewed research and female-specific data into a structured, citation-backed knowledge layer that other companies license by API, either as their product's entire women's-health database or to check one they already have. Its founding customers are Human Powered Health and Altra Running.

Why It Matters

Wearables, cycle trackers and AI health assistants are adding "hormonal insights" faster than the evidence behind them is being audited. That is the gap the [BMJ flagged in menstrual-tracking apps](/stories/bmj-menstrual-tracking-apps-harm) and that Spain's food-safety agency ran into when its [menopause guide turned out to rest on male reference data](/stories/aesan-menopause-guidance-male-data). CX is betting that "show me the research" becomes a procurement requirement for anyone marketing to women. It sells picks and shovels rather than another consumer app. Its first customers are in sports and performance, but the same API could sit under perimenopause, sexual-health and pelvic-floor products, where unsupported claims are common. The size of the round is a reminder of where femtech money is going in 2026: small, infrastructure-shaped bets rather than big consumer rounds.

The co-founders are CEO Lindsey Abramo and chief research officer Dr. Stacy Sims, an exercise physiologist well known for her work on female physiology. "Women have been systematically excluded from health research, with generational consequences," Sims said. "We pair vetted academic research with commercial scale, so companies, clinicians, and health and performance products can finally build on data designed for and from female bodies." The company's release says women weren't required in NIH-funded clinical trials until 1993. It also says AI models trained on that research default to male data, and that leading models "failed 60% of questions on a recent women's health benchmark." That benchmark figure is CX's own claim, and the release does not name the benchmark. A "Research Lead Collective" of more than 20 MDs and PhDs, headed by Sims, vets the research base. Performance company Momentous has committed $200,000 to a grant program for those researchers.

Femtech Insider and FemTech World both report that the money will expand the platform and its research across life stages and conditions. "Collective X's edge isn't a smarter model. It's a smarter foundation underneath the model," said Elizabeth Davis, partner at Anthemis Female Innovators Lab Fund.

Sources

Update — 2026-10-19

Initial entry — story first created.